Eculizumab biosimilars available in Europe and USA
There are now licensed biosimilars to eculizumab available in Europe and also in the USA ( see previous article and further…
aHUS is likely at any time of year
More data about the time of year for aHUS was collected in the recent aHUS Global Poll to add to that…
What’s New in aHUS Research: SEPT 2024 Edition
Every year since the first aHUS Awareness Day on 24 Sept 2015 we’ve attempted to shine a spotlight on atypical HUS…
Is aHUS’ end nigh? It is now!
Nearly five years ago Global Action asked the question “ Is aHUS’s end nigh ?” In a trilogy of articles. (…
COVID Infection and vaccination and aHUS.
It was anticipated at the beginning of the pandemic that COVID would be a trigger of aHUS. Global Action postulated it…
2024 Global aHUS Poll Launches
2024 survey launched to explore atypical HUS patient experiences around the world.
An eculizumab biosimilar for the USA
Global Action has received this notice from the FDA. We cannot find a price or evidence from an aHUS trial as…
Poems for aHUS,
While sorting out some papers recently I came across a poem an aHUS patient sent me about living with dialysis. This…
Topics in aHUS Global Advocacy: Oct 2023
Keeping current with advancements in atypical HUS knowledge is important for patient families as well as clinicians, but that’s no small…